Zoë got her Bachelor’s degree in Pharmacology from University of Bristol, UK, followed by her PhD in Pharmacology from University College London. After completing a post-doc at Oxford University, Zoë left academia to join the Neuroscience Research Unit at SmithKlineBeecham and subsequently the Psychiatry Centre of Excellence at GlaxoSmithKline. In 2004 Zoë moved to the USA to continue her career in Neuroscience drug discovery at Wyeth Research where she took on increasing leadership roles for preclinical drug discovery projects in the depression and anxiety field. After moving to Pfizer in 2010 she developed preclinical and translational approaches to address common domains of function affected in psychiatric and neurodegenerative disease. Zoë has held leadership roles on a number of projects which delivered candidates for clinical development; she also built a Translational Pharmacology lab focused on generating preclinical data to inform the design of early clinical studies across CNS disorders. Zoë’s research interests span psychiatry and neurodegeneration and has recently focused on the role of neuroinflammation in CNS disorders. She has actively contributed to a number of multi-national translational research consortia involving leading academic and industry groups and published her work in over 50 peer reviewed articles. While at Pfizer, Zoë led the FAAH inhibitor program where she gained support to re-position the molecule for PTSD. She was instrumental in this molecule being successfully out-licensed to SpringWorks Therapeutics, a small development company conceived by Pfizer. After getting a taste of the ‘start-up world’, in June 2018 Zoë joined Praxis Precision Medicines, a small biotech inspired by breakthroughs in the genetics of epilepsy and overlapping biology with broader neuropsychiatric disorders.